Inventor
YASOSHIMA KAYO
US15 patents
⚠️ This page may combine multiple inventors who share the name “YASOSHIMA KAYO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
5 patentsUS10005829B2Jun 26, 2018
Synthetic linear apelin mimetics for the treatment of heart failure
NOVARTIS AG3 citations72
US9908919B2Mar 6, 2018
Cyclic apelin derivatives for the treatment of heart failure
NOVARTIS AG3 citations72
US10844055B2Nov 24, 2020
Naphthyridinone derivatives and their use in the treatment of arrhythmia
NOVARTIS AG1 citations70
US11530213B2Dec 20, 2022
Naphthyridinone derivatives and their use in the treatment of arrhythmia
NOVARTIS AG0 citations59
US10266531B2Apr 23, 2019
Naphthyridinone derivatives and their use in the treatment of arrhythmia
NOVARTIS AG0 citations48
ZECRI FREDERIC
4 patentsUS8673848B2Mar 18, 2014
Synthetic apelin mimetics for the treatment of heart failure
ZECRI FREDERIC53 citations96
US9266925B2Feb 23, 2016
Cyclic polypeptides for the treatment of heart failure
ZECRI FREDERIC8 citations80
US9683018B2Jun 20, 2017
Disulfide cyclic polypeptides for the treatment of heart failure
ZECRI FREDERIC3 citations72
US9683019B2Jun 20, 2017
Cyclic polypeptides for the treatment of heart failure
ZECRI FREDERIC3 citations70
MOGI MUNETO
4 patentsUS8440682B2May 14, 2013
4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors
MOGI MUNETO0 citations48
US8420641B2Apr 16, 2013
Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives
MOGI MUNETO0 citations48
US8193349B2Jun 5, 2012
4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors
MOGI MUNETO0 citations48
US8759365B2Jun 24, 2014
Organic compounds
MOGI MUNETO0 citations39